Yes, absolutely. Prescribing by brand ensures the patient gets a familiar device that they can hopefully use each time it’s prescribed. It’s been known for a while in the inhaler market that prescribing beclometasone generically is a safety issue i.e. with Clenil, Qvar (fine particle) and now Kelhale (fine particle).
However, if Budesonide and Formoterol are prescribed generically these days in a DPI, the patient can potentially get 3 different devices in subsequent months that can lead to confusion e.g. double dosing (patient thinking it’s a new medicine), dissatisfaction, adherence issues, and potentially poor inhaler technique (if the patient isn’t coached on the new device).